← SynDRA
SURUFATINIB
SynDRA canonical compound SYN0039414 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | CSF1R | FGFR1 | KDR |
|---|
| Mechanism of action | tyrosine kinase inhibitor |
|---|
All known targets
- FGFR1
- KDR
- CSF1R
- FLT1
- FLT4
Mechanisms of action (all sources)
- FGFR1 INHIBITOR
- Fibroblast growth factor receptor 1 inhibitor
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
- KDR INHIBITOR
- tyrosine kinase inhibitor
- CSF1R INHIBITOR
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- HMPL-012
- Sulfatinib
- Anticancer agents, Hutchison
- Kinase inhibitors (cancer), Hutchison
- VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison
- B2K5L1L8S9
- surufatinibum
- RefChem:186832
- HMPL012
- Surufatinib [INN]
- Surufatinib [USAN]
- Sulanda
- Sulfatinib?
- UKI
- MFCD28359080
- Sulfatinib (Standard)
- Sulfatinib [WHO-DD]
- Sulfatinib; HMPL-012
- Surufatinib (USAN/INN)
- Surufatinib [USAN:INN]
- KDR-IN-1
- UNII-B2K5L1L8S9
- SURUFATINIB [WHO-DD]
- GTPL9769
- orb1303189
- SCHEMBL1822601
- SCHEMBL29363337
- SCHEMBL29366533
- C24H28N6O3S
- TTZSNFLLYPYKIL-UHFFFAOYSA-N
- GLXC-10726
- EX-A2524
- HY-12297R
- NSC797937
- WHO 10349
- AKOS030632837
- CS-5949
- NSC-797937
- NCGC00510476-02
Look up SURUFATINIB in the interactive SynDRA portal →